Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Ahmad R. Safa
Professor
Department of Oncology
Indiana University
USA
Professor Safa received his Ph. D. in MCDB in 1980 from Iowa State University.In 1987, he accepted a position as an Assistant Professor of Medicine at the University of Chicago and was Director of the Laboratories of Pharmacology and Pharmacokinetics, and Molecular Pharmacology, respectively in the Section of Hematology/Oncology from 1990-1996. In 1996, he accepted a tenured Associate Professor Position in the Department of Experimental Oncology, Medical University of South Carolina (MUSC), and was promoted to tenured Professor in 1999. Dr. Safa was Director of the Drug Resistance Program at Hollings Cancer Center at MUSC from 1998-1999. In 1999, he joined the faculty of the Indiana University School of Medicine as H.H. Gregg Professor of Cancer Research, and Professor of Pharmacology and Toxicology. Dr. Safa is also Director of the Graduate Program in the Department of Pharmacology and Toxicology.Dr. Safa served on the Experimental Therapeutics 1 Study Section at the NCI from 1988-2002, has been an Ad hoc Grant Reviewer, Center for Scientific Review, Drug Discovery and Molecular Pharmacology Study Section since 2003, Tumor cell Biology (TCB) Study Section, and Department of Defense (DOD) since 2007. He has been a member of the Editorial Board of International Journal of Cell Science & Molecular Biology (IJCSMB), Journal of Cancer Research and Therapeutic Oncology. Drug Research and Development, World Journal of Pharmacology, Medicinal Chemistry, Journal of Drug Metabolism and Toxicology, International Journal of Biochemistry and Molecular Biology, Journal of Cell Death, Molecular Cancer Therapeutics, and Investigational New Drugs.
His research interest includes multi-targeted therapy of pancreatic tumors, brain cancer, and breast cancer through modulation of the death receptor signaling pathway in cancer cells.
Make the best use of Scientific Research and information from our 700 + peer reviewed, 黑料网 Journals